+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Neoantigen Targeted Therapies Market by Therapy Modality (Adoptive Cell Therapy, Personalized Neoantigen Vaccines), Treatment Approach (Combination Therapy, Monotherapy), Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast 2025-2030- Product Image
Neoantigen Targeted Therapies Market by Therapy Modality (Adoptive Cell Therapy, Personalized Neoantigen Vaccines), Treatment Approach (Combination Therapy, Monotherapy), Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast 2025-2030- Product Image
Sale

Neoantigen Targeted Therapies Market by Therapy Modality (Adoptive Cell Therapy, Personalized Neoantigen Vaccines), Treatment Approach (Combination Therapy, Monotherapy), Route of Administration, Age Group, Target Disease Indication, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4896728
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Neoantigen targeted therapies are redefining the oncology landscape by enabling tailored, patient-centric strategies that harness individual tumor mutations for therapeutic intervention. Senior leaders in biopharma, clinical operations, and healthcare investment are strongly positioned to capitalize on the next wave of innovation and market evolution in this fast-growing sector.

Market Snapshot: Neoantigen Targeted Therapies Market

The Neoantigen Targeted Therapies Market grew from USD 4.57 billion in 2024 to USD 5.30 billion in 2025. It is expected to continue growing at a CAGR of 16.16%, reaching USD 11.24 billion by 2030.

Scope & Segmentation

This research comprehensively covers the competitive landscape, technological advancements, and strategic trends in the Neoantigen Targeted Therapies Market across regions and applications. The report breaks down the market into actionable segments for precise strategic planning:

  • Therapy Modality: Adoptive cell therapy, personalized neoantigen vaccines
  • Cell Therapy Types: CAR-T cell therapy, T cell receptor (TCR) therapy, tumor-infiltrating lymphocytes (TIL)
  • Vaccine Platforms: Dendritic cell (DC) vaccines, DNA/RNA-based vaccines, synthetic long peptide (SLP) vaccines
  • Treatment Approach: Combination therapy, monotherapy
  • Route of Administration: Oral, intramuscular, intravenous, subcutaneous
  • Age Group: Adult, geriatric, pediatric
  • Target Disease Indication: Bone cancer, colorectal cancer, gynecological cancer, non-small cell lung cancer, renal cell carcinoma
  • End-User: Academic & government research institutes, hospitals & clinics, specialty clinics
  • Regions: Americas, Europe, Middle East & Africa, Asia-Pacific (including detailed country-level coverage)
  • Notable Companies: Achilles Therapeutics, Agenus Inc., AstraZeneca, BioNTech, Bristol‑Myers Squibb, CureVac, Eli Lilly, EpiVax, F. Hoffmann-La Roche, Genentech, Gilead Sciences, GlaxoSmithKline, Gritstone bio, Immatics, Immunomic Therapeutics, IOVANCE Biotherapeutics, Medigene, Merck & Co., Moderna, Neon Therapeutics, Nykode Therapeutics, Pfizer, Precision Biologics, Valo Therapeutics, among others.

Key Takeaways for Senior Decision-Makers

  • Neoantigen targeted therapies are accelerating the shift toward highly personalized cancer treatments, using patient-specific tumor mutations to optimize clinical results and minimize non-target effects.
  • Technological integration—such as next-generation sequencing, advanced bioinformatics, and synthetic vaccine platforms—has streamlined discovery, antigen validation, and development timelines.
  • Collaboration models linking biopharma companies, academic research centers, and contract manufacturing experts are fueling clinical translation and enabling scalable production.
  • Value-based reimbursement trends and increasing payer recognition of long-term treatment value are incentivizing continued investment and adoption in healthcare systems globally.
  • Regulatory openness to adaptive trial frameworks and the use of real-world evidence is allowing faster movement from laboratory breakthroughs to clinical and commercial deployment.
  • Regional growth is driven by strong industry clusters in North America, capacity building in Europe and emerging economies, and large patient pools with regulatory momentum across Asia-Pacific.

Tariff Impact on Neoantigen Therapy Supply Chains

Recently enacted United States tariffs on critical reagents, peptides, and laboratory equipment have increased supply chain complexity for both R&D and scaled manufacturing. Companies are actively reevaluating sourcing strategies, diversifying suppliers, and localizing production to mitigate delays and cost increases. Clinical trial logistics now often require decentralized processing and close coordination to minimize disruptions linked to cross-border shipping and customs timelines. Forward-looking strategies focus on supply chain resilience, flexible sourcing, and digital logistics solutions to navigate these new risks effectively.

Methodology & Data Sources

This study draws from a robust multi-layered methodology, combining secondary research across journals, clinical registries, and patents with expert interviews and internal peer review. Proprietary databases, scenario analysis, and validation against real-world market sources underpin the report’s accuracy and depth.

Why This Report Matters

  • Enables strategic planning by providing granular breakdowns of modalities, applications, and regional market opportunities for the Neoantigen Targeted Therapies Market.
  • Supports risk mitigation and supply chain optimization with in-depth analysis of current and future tariff impacts.
  • Delivers actionable insights to align R&D, regulatory, and go-to-market strategies with the most relevant market forces and reimbursement models.

Conclusion

Neoantigen targeted therapies are poised to redefine oncology by offering individualized, durable treatments and new pathways for commercial growth. Strategic collaboration, data-driven innovation, and adaptive supply frameworks will shape the market’s future trajectory for industry leaders and innovators.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising demand for personalized immunotherapies driving neoantigen innovation
5.2. Development of non-viral vector platforms for in vivo delivery of neoantigen-encoding mRNA therapies
5.3. Emergence of combination regimens pairing neoantigen vaccines with immune checkpoint blockade therapies
5.4. Advances in lipid nanoparticle delivery systems for mRNA-based neoantigen vaccines in oncology
5.5. Clinical translation of personalized neoantigen-specific T cell receptor therapies in advanced melanoma patients
5.6. Technological advances fueling growth in neoantigen-targeted therapy market
5.7. Advances in multi-epitope neoantigen delivery systems enhancing immune responses against solid tumors
5.8. Regulatory framework evolution guiding clinical development of individualized neoantigen immunotherapies
5.9. AI and genomics transforming neoantigen discovery and development
5.10. Implementation of digital twin simulations to predict patient-specific neoantigen immune engagement in silico
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Neoantigen Targeted Therapies Market, by Therapy Modality
8.1. Introduction
8.2. Adoptive Cell Therapy
8.2.1. CAR-T Cell Therapy
8.2.2. T Cell Receptor (TCR) Therapy
8.2.3. Tumor-infiltrating lymphocytes (TIL)
8.3. Personalized Neoantigen Vaccines
8.3.1. Dendritic Cell (DC) Vaccines
8.3.2. DNA/ RNA-based Vaccines
8.3.3. Peptide (SLP) Vaccines
9. Neoantigen Targeted Therapies Market, by Treatment Approach
9.1. Introduction
9.2. Combination Therapy
9.3. Monotherapy
10. Neoantigen Targeted Therapies Market, by Route of Administration
10.1. Introduction
10.2. Oral
10.3. Parenteral
10.3.1. Intramuscular
10.3.2. Intravenous
10.3.3. Subcutaneous
11. Neoantigen Targeted Therapies Market, by Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Neoantigen Targeted Therapies Market, by Target Disease Indication
12.1. Introduction
12.2. Bone Cancer
12.3. Colorectal Cancer
12.4. Gynecological Cancer
12.5. Non-Small Cell Lung Cancer
12.6. Renal Cell Carcinoma
13. Neoantigen Targeted Therapies Market, by End-User
13.1. Introduction
13.2. Academic & Government Research Institutes
13.3. Hospitals & Clinics
13.4. Specialty Clinics
14. Americas Neoantigen Targeted Therapies Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Neoantigen Targeted Therapies Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Neoantigen Targeted Therapies Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Achilles Therapeutics Limited
17.3.2. Agenus Inc.
17.3.3. AstraZeneca plc
17.3.4. BioNTech SE
17.3.5. Bristol-Myers Squibb Company
17.3.6. CureVac N.V.
17.3.7. Eli Lilly and Company
17.3.8. EpiVax, Inc.
17.3.9. F. Hoffmann-La Roche AG
17.3.10. Genentech, Inc.
17.3.11. Genocea Biosciences, Inc.
17.3.12. Gilead Sciences, Inc.
17.3.13. GlaxoSmithKline plc
17.3.14. Gritstone bio, Inc.
17.3.15. Immatics N.V.
17.3.16. Immunomic Therapeutics, Inc.
17.3.17. IOVANCE Biotherapeutics, Inc.
17.3.18. Medigene AG
17.3.19. Merck & Co., Inc.
17.3.20. Moderna, Inc.
17.3.21. Neon Therapeutics, Inc.
17.3.22. Nykode Therapeutics
17.3.23. Pfizer Inc.
17.3.24. Precision Biologics
17.3.25. Valo Therapeutics Ltd
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. NEOANTIGEN TARGETED THERAPIES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NEOANTIGEN TARGETED THERAPIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NEOANTIGEN TARGETED THERAPIES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCHAI
FIGURE 28. NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCHSTATISTICS
FIGURE 29. NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCHCONTACTS
FIGURE 30. NEOANTIGEN TARGETED THERAPIES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NEOANTIGEN TARGETED THERAPIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY CAR-T CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY T CELL RECEPTOR (TCR) THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TUMOR-INFILTRATING LYMPHOCYTES (TIL), BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DENDRITIC CELL (DC) VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY DNA/ RNA-BASED VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEPTIDE (SLP) VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY BONE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY GYNECOLOGICAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 107. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 108. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 109. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 110. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 111. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 112. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 119. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 120. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 121. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 122. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 123. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 124. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 125. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 126. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 127. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 130. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 131. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 132. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 133. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 134. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 135. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 136. CANADA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 137. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 138. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 139. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 140. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 141. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 142. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 143. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 144. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 145. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 148. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 149. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 152. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 153. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 154. MEXICO NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 155. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 156. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 157. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 158. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 159. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 160. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 161. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 162. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 163. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 164. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 165. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 166. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 167. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 168. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 169. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 170. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 173. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 174. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 175. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 176. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 177. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 178. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 179. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 180. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 181. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 184. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 185. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 186. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 187. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 188. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 197. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 198. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 199. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 202. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 203. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 204. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 205. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 206. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 211. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 212. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 213. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 214. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 215. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 216. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 217. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 218. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 219. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 220. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 221. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 222. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 223. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 224. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 225. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 226. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 229. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 230. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 231. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 232. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 233. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 234. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 235. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 236. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 237. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 238. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 239. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 240. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 241. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 244. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 245. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 246. GERMANY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 247. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 248. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 249. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 250. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 251. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 252. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 253. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 254. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 255. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 258. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 259. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 262. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 263. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 264. FRANCE NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 265. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 266. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 267. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 268. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 269. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 270. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 271. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 272. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 273. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 274. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 275. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 276. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2025-2030 (USD MILLION)
TABLE 277. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
TABLE 278. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
TABLE 279. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 280. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TARGET DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 283. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2018-2024 (USD MILLION)
TABLE 284. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY THERAPY MODALITY, 2025-2030 (USD MILLION)
TABLE 285. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 286. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ADOPTIVE CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 287. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2018-2024 (USD MILLION)
TABLE 288. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PERSONALIZED NEOANTIGEN VACCINES, 2025-2030 (USD MILLION)
TABLE 289. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2018-2024 (USD MILLION)
TABLE 290. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY TREATMENT APPROACH, 2025-2030 (USD MILLION)
TABLE 291. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 292. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 293. ITALY NEOANTIGEN TARGETED THERAPIES MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
TABLE 294. ITALY NE

Samples

Loading
LOADING...

Companies Mentioned

  • Achilles Therapeutics Limited
  • Agenus Inc.
  • AstraZeneca plc
  • BioNTech SE
  • Bristol‑Myers Squibb Company
  • CureVac N.V.
  • Eli Lilly and Company
  • EpiVax, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • Genocea Biosciences, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Gritstone bio, Inc.
  • Immatics N.V.
  • Immunomic Therapeutics, Inc.
  • IOVANCE Biotherapeutics, Inc.
  • Medigene AG
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Neon Therapeutics, Inc.
  • Nykode Therapeutics
  • Pfizer Inc.
  • Precision Biologics
  • Valo Therapeutics Ltd

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 11.24 Billion
Compound Annual Growth Rate16.1%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Neoantigen Targeted Therapies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Neoantigen Targeted Therapies Market Report 2025 - Product Image

Neoantigen Targeted Therapies Market Report 2025

  • Report
  • 200 Pages
  • Global
From
T-Cell Therapy Market by Type of Therapy, Target Indication, Target Antigen, Company Size, Geographical Regions, Leading Players and Sales Forecast of Therapies, Industry Trends and Global Forecasts to 2035 - Product Image

T-Cell Therapy Market by Type of Therapy, Target Indication, Target Antigen, Company Size, Geographical Regions, Leading Players and Sales Forecast of Therapies, Industry Trends and Global Forecasts to 2035

  • Report
  • 1048 Pages
  • Global
From
Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030 - Product Image

Pancreatic Cancer Precision Medicine Market Size, Share & Trends Analysis Report by Therapeutic Approach (Targeted Therapy, Immunotherapy, Chemotherapy-Precision Combinations), Diagnostic Technology, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
CD19-targeted CAR-T Cell Therapy Market by Indication (Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma), Product Type (Allogeneic, Autologous), Line of Therapy, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

CD19-targeted CAR-T Cell Therapy Market by Indication (Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma), Product Type (Allogeneic, Autologous), Line of Therapy, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.